Jingoism buried, IPO done, stock price up 50%. What next for Gland Pharma?
Its IPO was talk of the town, but investors gave it a miss. Now, the company is having the last laugh
V Keshavdev - December 10, 2020
How KKR India reached a debt end
The marquee private equity firm’s strategy of lending to growth companies and risky turnarounds has backfired badly, denting its reputation as a savvy financier
Krishna Gopalan - January 24, 2020
